Jasper Therapeutics Gears Up for Major Investor Engagement Events
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a pioneering clinical-stage biotechnology company, is excited to announce its participation in two important investor conferences this September. The company is dedicated to developing briquilimab, a novel therapy that targets KIT (CD117) to address diseases driven by mast cells, including chronic spontaneous urticaria and asthma.
Upcoming Conferences
Cantor Fitzgerald Global Healthcare Conference 2025
Jasper will present at the Cantor Fitzgerald Global Healthcare Conference 2025, scheduled for September 3-5. Management will engage with investors through a fireside chat on Wednesday, September 3, at 1:00 PM EDT.
H.C. Wainwright 27th Annual Global Investment Conference
Following the Cantor Fitzgerald Conference, Jasper will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. The company’s fireside chat is set for Tuesday, September 9, at 3:00 PM EDT.
Accessing the Presentations
Live webcasts of the fireside chats will be available through the News & Events section on Jasper's Investor Relations website. Additionally, archived recordings of the presentations will be accessible for 30 days after the live events.
About Jasper Therapeutics
Jasper Therapeutics is at the forefront of innovation in the biotechnology sector, particularly in treating chronic mast cell diseases. At the core of its approach is briquilimab, a targeted monoclonal antibody designed to block the stem cell factor from binding to the KIT receptor on mast cells. This groundbreaking therapy has shown promising efficacy and safety in clinical trials for conditions such as chronic spontaneous urticaria and chronic inducible urticaria.
The Potential of Briquilimab
Briquilimab's distinct mechanism of action provides significant therapeutic potential. By inhibiting signaling through the KIT receptor, it disrupts the survival signals for mast cells, guiding them towards apoptosis. This process effectively reduces excessive mast cell activity, which is crucial for alleviating the inflammatory responses associated with various mast cell-driven disorders. Clinical studies are currently underway to establish the full therapeutic profile of briquilimab.
Connect with Jasper Therapeutics
For more information about Jasper Therapeutics and its innovative approach to chronic mast cell diseases, visit www.jaspertx.com.
Frequently Asked Questions
What is jasper Therapeutics focused on?
Jasper Therapeutics is focused on developing briquilimab, a treatment for mast cell-driven diseases such as chronic spontaneous urticaria and asthma.
When will the investor conferences take place?
The Cantor Fitzgerald Global Healthcare Conference is on September 3-5, and the H.C. Wainwright Conference is on September 8-10.
How can I access the presentations?
You can access live webcasts of the presentations through the Investor Relations page on Jasper's website.
What is briquilimab?
Briquilimab is a targeted monoclonal antibody that blocks signals from the stem cell factor to reduce mast cell activity.
What are the potential benefits of briquilimab?
The therapy aims to alleviate symptoms associated with mast cell-driven diseases by disrupting the survival signals of mast cells.
